Ophthalmologic considerations in using antimalarials in the United States
Ophthalmologic considerations continue to be important in the use of antimalarials. In the United States, hydroxychloroquine is prescribed much more frequently than chloroquine. Despite the favorable safety record, potential retinal problems cause patients to often be afraid to take antimalarial med...
Gespeichert in:
| Veröffentlicht in: | Lupus 1996-06, Vol.5 Suppl 1 (1_suppl), p.S73-74 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1_suppl |
| container_start_page | S73 |
| container_title | Lupus |
| container_volume | 5 Suppl 1 |
| creator | Rynes, R I |
| description | Ophthalmologic considerations continue to be important in the use of antimalarials. In the United States, hydroxychloroquine is prescribed much more frequently than chloroquine. Despite the favorable safety record, potential retinal problems cause patients to often be afraid to take antimalarial medicine. Ophthalmologic visits are recommended every three months by the drug manufacturer, but most often are scheduled every six months by physicians. Ophthalmologic examination includes questioning about visual symptoms, visual acuity tests, careful fundoscopic evaluation and a visual field assessment. Amsler grid self evaluation is not yet wide-spread. |
| doi_str_mv | 10.1177/0961203396005001171 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15693421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15693421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c246t-764ecc21c3a0e6a2f8629b43c3ebc025f2399d36b8842d2e680023ed1a72ef843</originalsourceid><addsrcrecordid>eNptkEtPwzAQhC0EKqXwCxBSTtwC60cd-4gqHpUq9QA9R46zaY3yKLZz4N_j0ooTp13tfDPSDiG3FB4oLYpH0JIy4FxLgDlAutEzMqWiKPIksXMyPRD5AbkkVyF8AgCnWk7IRCngmhZTslzvd3Fn2m5oh62zmR364Gr0Jrq0Za7PxuD6bWb66DrTGu9M-3uOO8w2vYtYZ-_RRAzX5KJJGt6c5oxsXp4_Fm_5av26XDytcsuEjHkhBVrLqOUGUBrWKMl0JbjlWFlg84ZxrWsuK6UEqxlKBcA41tQUDBsl-IzcH3P3fvgaMcSyc8Fi25oehzGUdC41F4wmkB9B64cQPDbl3qcf_HdJoTwUWP5TYHLdneLHqsP6z3NqjP8AvzJq_Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15693421</pqid></control><display><type>article</type><title>Ophthalmologic considerations in using antimalarials in the United States</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Rynes, R I</creator><creatorcontrib>Rynes, R I</creatorcontrib><description>Ophthalmologic considerations continue to be important in the use of antimalarials. In the United States, hydroxychloroquine is prescribed much more frequently than chloroquine. Despite the favorable safety record, potential retinal problems cause patients to often be afraid to take antimalarial medicine. Ophthalmologic visits are recommended every three months by the drug manufacturer, but most often are scheduled every six months by physicians. Ophthalmologic examination includes questioning about visual symptoms, visual acuity tests, careful fundoscopic evaluation and a visual field assessment. Amsler grid self evaluation is not yet wide-spread.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/0961203396005001171</identifier><identifier>PMID: 8803917</identifier><language>eng</language><publisher>England</publisher><subject>Antimalarials - administration & dosage ; Antimalarials - adverse effects ; Chloroquine - administration & dosage ; Chloroquine - adverse effects ; Humans ; Hydroxychloroquine - administration & dosage ; Hydroxychloroquine - adverse effects ; Retinal Diseases - chemically induced ; Retinal Diseases - diagnosis ; Safety ; United States ; Vision Tests - methods ; Visual Fields - drug effects</subject><ispartof>Lupus, 1996-06, Vol.5 Suppl 1 (1_suppl), p.S73-74</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c246t-764ecc21c3a0e6a2f8629b43c3ebc025f2399d36b8842d2e680023ed1a72ef843</citedby><cites>FETCH-LOGICAL-c246t-764ecc21c3a0e6a2f8629b43c3ebc025f2399d36b8842d2e680023ed1a72ef843</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8803917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rynes, R I</creatorcontrib><title>Ophthalmologic considerations in using antimalarials in the United States</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Ophthalmologic considerations continue to be important in the use of antimalarials. In the United States, hydroxychloroquine is prescribed much more frequently than chloroquine. Despite the favorable safety record, potential retinal problems cause patients to often be afraid to take antimalarial medicine. Ophthalmologic visits are recommended every three months by the drug manufacturer, but most often are scheduled every six months by physicians. Ophthalmologic examination includes questioning about visual symptoms, visual acuity tests, careful fundoscopic evaluation and a visual field assessment. Amsler grid self evaluation is not yet wide-spread.</description><subject>Antimalarials - administration & dosage</subject><subject>Antimalarials - adverse effects</subject><subject>Chloroquine - administration & dosage</subject><subject>Chloroquine - adverse effects</subject><subject>Humans</subject><subject>Hydroxychloroquine - administration & dosage</subject><subject>Hydroxychloroquine - adverse effects</subject><subject>Retinal Diseases - chemically induced</subject><subject>Retinal Diseases - diagnosis</subject><subject>Safety</subject><subject>United States</subject><subject>Vision Tests - methods</subject><subject>Visual Fields - drug effects</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkEtPwzAQhC0EKqXwCxBSTtwC60cd-4gqHpUq9QA9R46zaY3yKLZz4N_j0ooTp13tfDPSDiG3FB4oLYpH0JIy4FxLgDlAutEzMqWiKPIksXMyPRD5AbkkVyF8AgCnWk7IRCngmhZTslzvd3Fn2m5oh62zmR364Gr0Jrq0Za7PxuD6bWb66DrTGu9M-3uOO8w2vYtYZ-_RRAzX5KJJGt6c5oxsXp4_Fm_5av26XDytcsuEjHkhBVrLqOUGUBrWKMl0JbjlWFlg84ZxrWsuK6UEqxlKBcA41tQUDBsl-IzcH3P3fvgaMcSyc8Fi25oehzGUdC41F4wmkB9B64cQPDbl3qcf_HdJoTwUWP5TYHLdneLHqsP6z3NqjP8AvzJq_Q</recordid><startdate>199606</startdate><enddate>199606</enddate><creator>Rynes, R I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>199606</creationdate><title>Ophthalmologic considerations in using antimalarials in the United States</title><author>Rynes, R I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c246t-764ecc21c3a0e6a2f8629b43c3ebc025f2399d36b8842d2e680023ed1a72ef843</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Antimalarials - administration & dosage</topic><topic>Antimalarials - adverse effects</topic><topic>Chloroquine - administration & dosage</topic><topic>Chloroquine - adverse effects</topic><topic>Humans</topic><topic>Hydroxychloroquine - administration & dosage</topic><topic>Hydroxychloroquine - adverse effects</topic><topic>Retinal Diseases - chemically induced</topic><topic>Retinal Diseases - diagnosis</topic><topic>Safety</topic><topic>United States</topic><topic>Vision Tests - methods</topic><topic>Visual Fields - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rynes, R I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rynes, R I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ophthalmologic considerations in using antimalarials in the United States</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>1996-06</date><risdate>1996</risdate><volume>5 Suppl 1</volume><issue>1_suppl</issue><spage>S73</spage><epage>74</epage><pages>S73-74</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Ophthalmologic considerations continue to be important in the use of antimalarials. In the United States, hydroxychloroquine is prescribed much more frequently than chloroquine. Despite the favorable safety record, potential retinal problems cause patients to often be afraid to take antimalarial medicine. Ophthalmologic visits are recommended every three months by the drug manufacturer, but most often are scheduled every six months by physicians. Ophthalmologic examination includes questioning about visual symptoms, visual acuity tests, careful fundoscopic evaluation and a visual field assessment. Amsler grid self evaluation is not yet wide-spread.</abstract><cop>England</cop><pmid>8803917</pmid><doi>10.1177/0961203396005001171</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0961-2033 |
| ispartof | Lupus, 1996-06, Vol.5 Suppl 1 (1_suppl), p.S73-74 |
| issn | 0961-2033 1477-0962 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15693421 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Antimalarials - administration & dosage Antimalarials - adverse effects Chloroquine - administration & dosage Chloroquine - adverse effects Humans Hydroxychloroquine - administration & dosage Hydroxychloroquine - adverse effects Retinal Diseases - chemically induced Retinal Diseases - diagnosis Safety United States Vision Tests - methods Visual Fields - drug effects |
| title | Ophthalmologic considerations in using antimalarials in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T07%3A50%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ophthalmologic%20considerations%20in%20using%20antimalarials%20in%20the%20United%20States&rft.jtitle=Lupus&rft.au=Rynes,%20R%20I&rft.date=1996-06&rft.volume=5%20Suppl%201&rft.issue=1_suppl&rft.spage=S73&rft.epage=74&rft.pages=S73-74&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/0961203396005001171&rft_dat=%3Cproquest_cross%3E15693421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15693421&rft_id=info:pmid/8803917&rfr_iscdi=true |